Gregory St John

1.1k citations
28 papers · 825 · h-index 12

Impact in

  • Biochemistry top 5%
    • Sulfur Compounds in Biology
  • Rheumatology top 5%
    • Rheumatoid Arthritis Research and Therapies
    • Systemic Lupus Erythematosus Research

Papers in

  • Rheumatology 19
    • Rheumatoid Arthritis Research and Therapies 19
    • Systemic Lupus Erythematosus Research 7
  • Hematology 9
    • Autoimmune and Inflammatory Disorders Research 9
Co-authors
Carl Nathan (4 shared papers)Nathan Brot (3 shared papers)Herbert Weissbach (2 shared papers)Jia Ruan (2 shared papers)Stefan H. Heinemann (1 shared paper)W. Todd Lowther (1 shared paper)Brian W. Matthews (1 shared paper)Toshinori Hoshi (1 shared paper)
Journals
Annals of the Rheumatic Diseases (11 papers)Lara D. Veeken (4 papers)Arthritis Research & Therapy (2 papers)RMD Open (2 papers)Molecular Microbiology (1 paper)
Partner nations
United StatesGermanySpain

In The Last Decade

Gregory St John

27 papers receiving 810 citations

Peers

Gregory St John
Comparison fields: 5 of 103
  • Biochemistry 101
  • Rheumatology 187
  • Molecular Medicine 34
  • Hematology 76
  • Infectious Diseases 115
Replace Hironobu Eguchi with:
Hironobu Eguchi Japan
Giovanna Valentini Italy
Tao-Hsin Chang Taiwan
Peter W. Melera United States
Josy ter Beek Sweden
Hyun Sik Jun South Korea
Gregory Tombline United States
Andrea Wagner Germany
Ritu Chakravarti United States
Keiichi Hosokawa Japan
Gregory St John relative to Hironobu Eguchi Japan Hironobu Eguchi's profile →
Citations per field
00.5×2×4×6.4×
Hironobu Eguchi · 1×
Citations per year

Countries citing papers authored by Gregory St John

Since Specialization
Citations

This map shows the geographic impact of Gregory St John's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory St John with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory St John more than expected).

Fields of papers citing papers by Gregory St John

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory St John. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory St John. The network helps show where Gregory St John may publish in the future.

Co-authors

The 25 scholars most cited alongside Gregory St John, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gregory St John Line = papers co-authored together Gregory St John links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Peptide Methionine Sulfoxide Reductase: Structure, Mechanism of Action, and Biological Function
Archives of Biochemistry and Biophysics ·Herbert Weissbach, Frantzy Etienne, Toshinori Hoshi, Stefan H. Heinemann, W. Todd Lowther, Brian W. Matthews, Gregory St John, Carl Nathan, Nathan Brot
2002268
2
Peptide methionine sulfoxide reductase fromEscherichia coliandMycobacterium tuberculosisprotects bacteria against oxidative damage from reactive nitrogen intermediates
Proceedings of the National Academy of Sciences ·Gregory St John, Nathan Brot, Jia Ruan, Hediye Erdjument‐Bromage, Paul Tempst, Herbert Weissbach, Carl Nathan
2001170
3
Mycobacterium tuberculosis expresses methionine sulphoxide reductases A and B that protect from killing by nitrite and hypochlorite
Molecular Microbiology ·Warren L. Lee, Benjamin D. Gold, Crystal M. Darby, Nathan Brot, Xiuju Jiang, Luiz Pedro S. de Carvalho, Daniel Wellner, Gregory St John, William R. Jacobs, Carl Nathan
200863
4
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up
Lara D. Veeken ·Roy Fleischmann, Mark C. Genovese, Yong Lin, Gregory St John, Désirée van der Heijde, Sheldon Wang, Juan J. Gómez‐Reino, José A. Maldonado‐Cocco, Marina Stanislav, Alan Kivitz, Gerd R Burmester
201955
5
noxR3 , a Novel Gene from Mycobacterium tuberculosis , Protects Salmonella typhimurium from Nitrosative and Oxidative Stress
Infection and Immunity ·Jia Ruan, Gregory St John, Sabine Ehrt, Lee Riley, Carl Nathan
199947
6
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
Annals of the Rheumatic Diseases ·Dimitrios A. Pappas, Gregory St John, Carol J. Etzel, Stefano Fiore, Taylor Blachley, Toshio Kimura, Rajeshwari Punekar, Kelechi Emeanuru, Jeannie Choi, Susan Boklage, Joel M. Kremer
202033
7
Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters
The Journal of Clinical Pharmacology ·Christine Xu, Ashique Rafique, Terra Potocky, Anne Paccaly, Patrick Nolain, Qiang Lü, Melitza Iglesias‐Rodriguez, Gregory St John, Michael C. Nivens, Vanaja Kanamaluru, Jeanette Fairhurst, Tomonori Ishii, Rafaël Maldonado, Ernest Choy, Paul Emery
202032
8
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
RMD Open ·Mark C. Genovese, Désirée van der Heijde, Yong Lin, Gregory St John, Sheldon Wang, Hubert van Hoogstraten, Juan J. Gómez‐Reino, Alan Kivitz, José A. Maldonado‐Cocco, B. Seriolo, Marina Stanislav, Gerd R Burmester
201929
9
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
Arthritis Research & Therapy ·Mark C. Genovese, Roy Fleischmann, Alan Kivitz, Eun Bong Lee, Hubert van Hoogstraten, Toshio Kimura, Gregory St John, Erin Mangan, Gerd R Burmester
202026
10
Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials
Arthritis Research & Therapy ·Mark C. Genovese, Gerd R Burmester, Owen Hagino, Karthinathan Thangavelu, Melitza Iglesias‐Rodriguez, Gregory St John, Miguel Á. González‐Gay, Thomas Mandrup‐Poulsen, Roy Fleischmann
202026
11
Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
ACR Open Rheumatology ·Paul Emery, Hubert van Hoogstraten, Karthinathan Thangavelu, Erin Mangan, Gregory St John, Patrick Verschueren
202015
12
Data‐Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Arthritis Care & Research ·Jeffrey R. Curtis, Michael E. Weinblatt, Kenneth G. Saag, Vivian P. Bykerk, Daniel E. Furst, Stefano Fiore, Gregory St John, Toshio Kimura, Shen Zheng, Clifton O. Bingham, Grace C. Wright, Martin Bergman, Kamala Nola, Christina Charles‐Schoeman, Nancy A. Shadick
202013
13
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
CPT Pharmacometrics & Systems Pharmacology ·Pavel Kovalenko, Anne Paccaly, Anita Boyapati, Christine Xu, Gregory St John, Michael C. Nivens, John D. Davis, Ronda Rippley, A. Thomas DiCioccio
20209
14
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
RMD Open ·Gerd R Burmester, Vibeke Strand, Andrea Rubbert‐Roth, Howard Amital, Т. А. Раскина, Antonio Gómez-Centeno, Claudia Pena-Rossi, Leon Gervitz, Karthinathan Thangavelu, Gregory St John, Susan Boklage, Mark C. Genovese
20199
15
A 2.4GHz non-contact biosensor system for continuous vital-signs monitoring
Ravi Ichapurapu, Suyash Jain, Gregory St John, Timothy Monday, Donald Y.C. Lie, Ron E. Banister, John Griswold
20099
16
FRI0106 SARILUMAB AND TOCILIZUMAB RECEPTOR OCCUPANCY (RO), AND EFFECTS ON C-REACTIVE PROTEIN (CRP) LEVELS, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
Annals of the Rheumatic Diseases ·Christine Xu, Patrick Nolain, Qiang Lü, Anne Paccaly, Melitza Iglesias‐Rodriguez, Gregory St John, Chad Nivens, Rafaël Maldonado, Tomonori Ishii, Ernest Choy, Vanaja Kanamaluru
20194
17
E064 The relationship between lipid profile changes and inflammation across the Phase 3 sarilumab rheumatoid arthritis (RA) development programme
Lara D. Veeken ·Christina Charles‐Schoeman, Gregory St John, Henry Leher, Toshio Kimura, Hubert van Hoogstraten, Michael T. Nurmohamed, Miguel Á. González‐Gay, Elaine Wilson, Edward Keystone
20193
18
081 Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up
Lara D. Veeken ·R. Fleischmann, Yong Lin, Gregory St John, Désirée van der Heijde, Chunfu Qiu, Juan Carlos Gomez-Reino, José A. Maldonado‐Cocco, Marina Stanislav, B. Seriolo, Lesley Tranter, Gerd R Burmester
20192
19
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
Annals of the Rheumatic Diseases ·Roy Fleischmann, Yong Lin, Gregory St John, Désirée van der Heijde, Chunfu Qiu, Juan J. Gómez‐Reino, José A. Maldonado‐Cocco, Marina Stanislav, B. Seriolo, Gerd R Burmester
20192
20
SAT0137 PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE)
Annals of the Rheumatic Diseases ·Gerd R Burmester, Howard Amital, Andrea Rubbert‐Roth, Hubert van Hoogstraten, Leon Gervitz, Karthinathan Thangavelu, Gregory St John, Mark C. Genovese
20192

About Gregory St John

Gregory St John is a scholar working on Rheumatology, Hematology, Genetics, Molecular Biology and Neurology, having authored 28 papers that have together received 825 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (19 papers), Autoimmune and Inflammatory Disorders Research (9 papers), Systemic Lupus Erythematosus Research (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Peripheral Neuropathies and Disorders (3 papers), Sulfur Compounds in Biology (2 papers), Acute Lymphoblastic Leukemia research (2 papers) and Pharmaceutical studies and practices (2 papers). The work is most often cited by research in Biochemistry (101 citations), Rheumatology (187 citations), Molecular Medicine (34 citations), Hematology (76 citations) and Infectious Diseases (115 citations). Gregory St John has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Carl Nathan, Nathan Brot, Herbert Weissbach, Jia Ruan, Stefan H. Heinemann, W. Todd Lowther, Brian W. Matthews, Toshinori Hoshi, Paul Tempst and Hediye Erdjument‐Bromage. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, Arthritis Research & Therapy, RMD Open and Molecular Microbiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hironobu EguchiBreakdown of academic impact, for papers by Giovanna ValentiniBreakdown of academic impact, for papers by Tao-Hsin ChangBreakdown of academic impact, for papers by Peter W. MeleraBreakdown of academic impact, for papers by Josy ter BeekBreakdown of academic impact, for papers by Hyun Sik JunBreakdown of academic impact, for papers by Gregory TomblineBreakdown of academic impact, for papers by Andrea WagnerBreakdown of academic impact, for papers by Ritu ChakravartiBreakdown of academic impact, for papers by Keiichi Hosokawa